An open‐label randomized study of the relative absorption of gastro‐resistant risedronate taken fasted or with food versus immediate‐release risedronate
Abstract Patients with osteoporosis often take oral bisphosphonates with food, rendering these medications ineffective. This study compared the relative absorption of four formulations of gastro‐resistant (GR; formulations 1-4) risedronate 35 mg versus immediate‐release (IR) risedronate 35 mg taken...
Saved in:
Main Authors: | Diane Kleinermans (Author), Andrew Joyson (Author), Heather Wray (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Once-monthly risedronate for postmenopausal osteoporosis
by: Kristina Casadei, et al.
Published: (2009) -
Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation
by: Boyanov M, et al.
Published: (2012) -
Risedronate-loaded aerogel scaffolds for bone regeneration
by: Nahla El-Wakil, et al.
Published: (2023) -
Evalution the Effects of Raloxifene and Risedronate on Serum Biochemical Markers
by: Abdurrahman Yeter, et al.
Published: (2014) -
<strong>The controlled release profile of risedronate emulgel to inhibit relapse movement in orthodontic treatment</strong>
by: Tita Ratya Utari, et al.
Published: (2022)